The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States
Authors:
- Y. Vivian TsaiYTY. Vivian Tsai
- P. Brandon BookstaverP. Brandon Bookstaver
- Julie Ann JustoJJJulie Ann Justo
- Darrell ChildressDCDarrell Childress
- Stefanie StramelSSStefanie Stramel
- Douglas SlainDSDouglas Slain
- Patrick TuPTPatrick Tu
- Mary Joyce B. WinglerMWMary Joyce B. Wingler
- Bruce M. JonesBJBruce M. Jones
- Megan M. SeddonMSMegan M. Seddon
Open Access
- 18 March 2024
- journal article
- research article
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 4 (1) , e35
Abstract
Objective: To evaluate temporal trends in the prevalence of gram-negative bacteria (GNB) with difficult-to-treat resistance (DTR) in the southeastern United States. Secondary objective was to examine the use of novel β-lactams for GNB with DTR by both antimicrobial use (AU) and a novel metric of adjusted AU by microbiological burden (am-AU).Design: Retrospective, multicenter, cohort.Setting: Ten hospitals in the southeastern United States.Methods: GNB with DTR including Enterobacterales,Pseudomonas aeruginosa, andAcinetobacterspp. from 2015 to 2020 were tracked at each institution. Cumulative AU of novel β-lactams including ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilastatin/relebactam, and cefiderocol in days of therapy (DOT) per 1,000 patient-days was calculated. Linear regression was utilized to examine temporal trends in the prevalence of GNB with DTR and cumulative AU of novel β-lactams.Results: The overall prevalence of GNB with DTR was 0.85% (1,223/143,638) with numerical increase from 0.77% to 1.00% between 2015 and 2020 (P= .06). There was a statistically significant increase in DTR Enterobacterales (0.11% to 0.28%,P= .023) and DTRAcinetobacterspp. (4.2% to 18.8%,P= .002). Cumulative AU of novel β-lactams was 1.91 ± 1.95 DOT per 1,000 patient-days. When comparing cumulative mean AU and am-AU, there was an increase from 1.91 to 2.36 DOT/1,000 patient-days, with more than half of the hospitals shifting in ranking after adjustment for microbiological burden.Conclusions: The overall prevalence of GNB with DTR and the use of novel β-lactams remain low. However, the uptrend in the use of novel β-lactams after adjusting for microbiological burden suggests a higher utilization relative to the prevalence of GNB with DTR.Keywords
This publication has 12 references indexed in Scilit:
- Novel method of calculating adjusted antibiotic use by microbiological burdenInfection Control & Hospital Epidemiology, 2021
- The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: CefiderocolFrontiers in Pharmacology, 2021
- Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving TargetClinical Infectious Diseases, 2020
- Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor CombinationsCurrent Infectious Disease Reports, 2019
- Direct Measurement of Performance: A New Era in Antimicrobial StewardshipAntibiotics, 2019
- External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US HospitalsOpen Forum Infectious Diseases, 2019
- Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor CombinationsDrugs, 2017
- Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaClinical Infectious Diseases, 2016
- Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their ImpactCurrent Treatment Options in Infectious Diseases, 2014
- Measurement of Adult Antibacterial Drug Use in 130 US Hospitals: Comparison of Defined Daily Dose and Days of TherapyClinical Infectious Diseases, 2007